首页> 外国专利> TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE

TEST-SYSTEM FOR PREDICTION OF RELAPSE DEVELOPMENT IN PATIENTS WITH UTERINE CORPUS CANCER BASED ON EXPRESSION LEVEL OF THE ESR1 GENE

机译:基于ESR1基因表达水平的子宫内膜癌患者预后预测的测试系统

摘要

FIELD: biotechnology.;SUBSTANCE: invention relates to molecular biology, oncology and biotechnology. Test-system for the prediction of relapses in patients with uterine corpus cancer, based on the level of expression of the ESR1 gene, contains control mixtures and a mixture for the real-time PCR reaction comprising 1 mM dNTPs, 12.5 mM MgCl2, 5-fold PCR-buffer with 5-fold dye EvaGreen Dye, DNA polymerase Thermus aquaticus in an amount of 5 U/mcl and highly specific oligonucleotide primers for genes ESR1 and ACTB.;EFFECT: invention provides a simple and accurate prediction of relapse in patients diagnosed with uterine corpus cancer without the use of expensive equipment, as well as high sensitivity and specificity.;1 cl, 1 tbl, 2 ex
机译:技术领域:本发明涉及分子生物学,肿瘤学和生物技术。基于ESR1基因表达水平的子宫体癌患者复发预测测试系统,包含对照混合物和包含1 mM dNTPs,12.5 mM MgCl 的实时PCR反应混合物2 ,5倍PCR缓冲液,5倍染料EvaGreen Dye,DNA聚合酶水生栖热菌(Thermus aquaticus),用量为5U / mcl,以及针对ESR1和ACTB基因的高度特异性的寡核苷酸引物。无需使用昂贵的设备以及高灵敏度和高特异性即可准确诊断出诊断为子宫体癌的患者的复发。1cl,1 tbl,2 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号